Cáncer de páncreas

Referencias

Artículos principales

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma [internet publication].Texto completo

Sohal DPS, Kennedy EB, Khorana A, et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018 Aug 20;36(24):2545-56.Texto completo  Resumen

Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703.Texto completo  Resumen

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25.Texto completo  Resumen

Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016 Aug 1;34(22):2654-68.Texto completo  Resumen

Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(5 suppl):v56-68.Texto completo  Resumen

Artículos de referencia

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma [internet publication].Texto completo

2. Noë M, Brosens LA. Pathology of pancreatic cancer precursor lesions. Surg Pathol Clin. 2016 Dec;9(4):561-80. Resumen

3. Klimstra DS, Pitman MB, Hruban RH. An algorithmic approach to the diagnosis of pancreatic neoplasms. Arch Pathol Lab Med. 2009 Mar;133(3):454-64.Texto completo  Resumen

4. Hruban RH, Adsay NV. Molecular classification of neoplasms of the pancreas. Hum Pathol. 2009 May;40(5):612-23. Resumen

5. Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005 Aug;129(2):504-11.Texto completo  Resumen

6. Sadr-Azodi O, Oskarsson V, Discacciati A, et al. Pancreatic cancer following acute pancreatitis: a population-based matched cohort study. Am J Gastroenterol. 2018 Nov;113(11):1711-9. Resumen

7. Diaconu C, Mateescu D, Bălăceanu A, et al. Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report. J Med Life. 2010 Jan-Mar;3(1):96-9.Texto completo  Resumen

8. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33.Texto completo  Resumen

9. Carrato A, Falcone A, Ducreux M, et al. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 2015 Sep;46(3):201-11.Texto completo  Resumen

10. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018 Nov;103:356-87. Resumen

11. Lynch SM, Vrieling A, Lubin JH, et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium. Am J Epidemiol. 2009 Aug 15;170(4):403-13.Texto completo  Resumen

12. Iodice S, Gandini S, Maisonneuve P, et al. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008 Jul;393(4):535-45. Resumen

13. Del Chiaro M, Zerbi A, Capurso G, et al. Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: a position paper from the Italian Registry. Dig Liver Dis. 2010 Sep;42(9):597-605. Resumen

14. Hruban RH, Maitra A, Schulick R, et al. Emerging molecular biology of pancreatic cancer. Gastrointest Cancer Res. 2008 Jul;2(4 Suppl):S10-5.Texto completo  Resumen

15. Petersen GM, de Andrade M, Goggins M, et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):704-10.Texto completo  Resumen

16. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med. 2009 Mar;133(3):365-74.Texto completo  Resumen

17. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007 Aug;56(8):1134-52.Texto completo  Resumen

18. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol. 2008 Jan 1;1(4):306-16.Texto completo  Resumen

19. Hechtman JF. NTRK insights: best practices for pathologists. Mod Pathol. 2022 Mar;35(3):298-305.Texto completo  Resumen

20. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004 Apr 1;64(7):2634-8.Texto completo  Resumen

21. Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000 Sep 15;87(6):809-11.Texto completo  Resumen

22. Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology. 2020 Jul;159(1):358-62.Texto completo  Resumen

23. Malka D, Hammel P, Maire F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002 Dec;51(6):849-52.Texto completo  Resumen

24. Aune D, Greenwood DC, Chan DS, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol. 2012 Apr;23(4):843-52.Texto completo  Resumen

25. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009 Jun 24;301(24):2553-62.Texto completo  Resumen

26. Jiao L, Silverman DT, Schairer C, et al. Alcohol use and risk of pancreatic cancer: the NIH-AARP Diet and Health Study. Am J Epidemiol. 2009 May 1;169(9):1043-51.Texto completo  Resumen

27. Hart AR, Kennedy H, Harvey I. Pancreatic cancer: a review of the evidence on causation. Clin Gastroenterol Hepatol. 2008 Mar;6(3):275-82. Resumen

28. Paluszkiewicz P, Smolińska K, Dębińska I, et al. Main dietary compounds and pancreatic cancer risk. The quantitative analysis of case-control and cohort studies. Cancer Epidemiol. 2012 Feb;36(1):60-7. Resumen

29. Ghadirian P, Simard A, Baillargeon J. Tobacco, alcohol, and coffee and cancer of the pancreas. A population-based, case-control study in Quebec, Canada. Cancer. 1991 May 15;67(10):2664-70. Resumen

30. Bond-Smith G, Banga N, Hammond TM, et al. Pancreatic adenocarcinoma. BMJ. 2012 May 16;344:e2476. Resumen

31. Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009 Jan;10(1):88-95.Texto completo  Resumen

32. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Dec 2021 [internet publication].Texto completo

33. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017 Jan;112(1):18-35.Texto completo  Resumen

34. Harsha HC, Kandasamy K, Ranganathan P, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009 Apr 7;6(4):e1000046.Texto completo  Resumen

35. Sohal DP, Mangu PB, Khorana AA, et al. Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016 Aug 10;34(23):2784-96.Texto completo  Resumen

36. National Institute for Health and Care Excellence. Pancreatic cancer in adults: diagnosis and management. Feb 2018 [internet publication].Texto completo

37. Zhao W-Y, Luo M, Sun YW, et al. Computed tomography in diagnosing vascular invasion in pancreatic and periampullary cancers: a systematic review and meta-analysis. Hepatobiliary Pancreat Dis Int. 2009 Oct;8(5):457-64. Resumen

38. Catalano C, Laghi A, Fraioli F, et al. Pancreatic carcinoma: the role of high-resolution multislice spiral CT in the diagnosis and assessment of resectability. Eur Radiol. 2003 Jan;13(1):149-56. Resumen

39. Expert Panel on Gastrointestinal Imaging; Qayyum A, Tamm EP, Kamel IR, Allen PJ, et al. ACR appropriateness criteria® staging of pancreatic ductal adenocarcinoma. J Am Coll Radiol. 2017 Nov;14(11S):S560-9.Texto completo  Resumen

40. Wu LM, Hu JN, Hua J, et al. Diagnostic value of diffusion-weighted magnetic resonance imaging compared with fluorodeoxyglucose positron emission tomography/computed tomography for pancreatic malignancy: a meta-analysis using a hierarchical regression model. J Gastroenterol Hepatol. 2012 Jun;27(6):1027-35.Texto completo  Resumen

41. Wu LM, Xu JR, Hua J, et al. Value of diffusion-weighted imaging for the discrimination of pancreatic lesions: a meta-analysis. Eur J Gastroenterol Hepatol. 2012 Feb;24(2):134-42. Resumen

42. Tang S, Huang G, Liu J, et al. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur J Radiol. 2011 Apr;78(1):142-50. Resumen

43. Farma JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol. 2008 Sep;15(9):2465-71.Texto completo  Resumen

44. Tummala P, Junaidi O, Agarwal B. Imaging of pancreatic cancer: An overview. J Gastrointest Oncol. 2011 Sep;2(3):168-74.Texto completo  Resumen

45. Adamek HE, Albert J, Breer H, et al. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet. 2000 Jul 15;356(9225):190-3. Resumen

46. Barish MA, Yucel EK, Ferrucci JT. Magnetic resonance cholangiopancreatography. N Engl J Med. 1999 Jul 22;341(4):258-64. Resumen

47. Lopez Hänninen E, Amthauer H, Hosten N, et al. Prospective evaluation of pancreatic tumors: accuracy of MR imaging with MR cholangiopancreatography and MR angiography. Radiology. 2002 Jul;224(1):34-41. Resumen

48. Dewitt J, Devereaux BM, Lehman GA, et al. Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. Clin Gastroenterol Hepatol. 2006 Jun;4(6):717-25. Resumen

49. Hewitt MJ, McPhail MJ, Possamai L, et al. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointest Endosc. 2012 Feb;75(2):319-31. Resumen

50. Ngamruengphong S, Swanson KM, Shah ND, et al. Preoperative endoscopic ultrasound-guided fine needle aspiration does not impair survival of patients with resected pancreatic cancer. Gut. 2015 Jul;64(7):1105-10. Resumen

51. Rustagi T, Gleeson FC, Chari ST, et al. Safety, diagnostic accuracy, and effects of endoscopic ultrasound fine-needle aspiration on detection of extravascular migratory metastases. Clin Gastroenterol Hepatol. 2019 Nov;17(12):2533-40.e1.Texto completo  Resumen

52. ASGE Standards of Practice Committee; Forbes N, Coelho-Prabhu N, Al-Haddad MA, et al. Adverse events associated with EUS and EUS-guided procedures. Gastrointest Endosc. 2022 Jan;95(1):16-26.e2.Texto completo  Resumen

53. Maithel SK, Maloney S, Winston C, et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2008 Dec;15(12):3512-20. Resumen

54. Hori Y; SAGES Guidelines Committee. Diagnostic laparoscopy guidelines. Surg Endosc. 2008 May;22(5):1353-83. Resumen

55. Hariharan D, Constantinides VA, Froeling FE, et al. The role of laparoscopy and laparoscopic ultrasound in the preoperative staging of pancreatico-biliary cancers: a meta-analysis. Eur J Surg Oncol. 2010 Oct;36(10):941-8. Resumen

56. Hartwig W, Schneider L, Diener MK, et al. Preoperative tissue diagnosis for tumours of the pancreas. Br J Surg. 2009 Jan;96(1):5-20. Resumen

57. Micames C, Jowell PS, White R, et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc. 2003 Nov;58(5):690-5. Resumen

58. Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020 Aug 5:JCO2001364.Texto completo  Resumen

59. Siriwardena AK, Siriwardena AM. Pancreatic cancer. BMJ. 2014 Oct 31;349:g6385. Resumen

60. Sohal DPS, Kennedy EB, Khorana A, et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018 Aug 20;36(24):2545-56.Texto completo  Resumen

61. Kloppel G, Adsay NV. Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch Pathol Lab Med. 2009 Mar;133(3):382-7. Resumen

62. Finkelberg DL, Sahani D, Deshpande V, et al. Autoimmune pancreatitis. N Engl J Med. 2006 Dec 21;355(25):2670-6. Resumen

63. Exocrine and endocrine pancreas. In: Amin MB, Edge S, Greene F, et al, eds. AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.

64. Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Gastroenterology. 2014 Jan;146(1):291-304. Resumen

65. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic [internet publication].Texto completo

66. Sawhney MS, Calderwood AH, Thosani NC, et al. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc. 2022 May;95(5):817-26.Texto completo  Resumen

67. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for pancreatic cancer: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019 Aug 6;322(5):438-44.Texto completo  Resumen

68. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004 Mar 27;363(9414):1049-57. Resumen

69. La Torre M, Nigri G, Ferrari L, et al. Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg. 2012 Feb;78(2):225-9. Resumen

70. Hüttner FJ, Fitzmaurice C, Schwarzer G, et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev. 2016 Feb 16;(2):CD006053.Texto completo  Resumen

71. Iqbal N, Lovegrove RE, Tilney HS, et al. A comparison of pancreaticoduodenectomy with pylorus preserving pancreaticoduodenectomy: a meta-analysis of 2822 patients. Eur J Surg Oncol. 2008 Nov;34(11):1237-45. Resumen

72. Hüttner FJ, Klotz R, Ulrich A, et al. Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy. Cochrane Database Syst Rev. 2022 Jan 11;1:CD011862.Texto completo  Resumen

73. Iqbal N, Lovegrove RE, Tilney HS, et al. A comparison of pancreaticoduodenectomy with extended pancreaticoduodenectomy: a meta-analysis of 1909 patients. Eur J Surg Oncol. 2009 Jan;35(1):79-86. Resumen

74. Jang JY, Kang MJ, Heo JS, et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg. 2014 Apr;259(4):656-64. Resumen

75. Glanemann M, Shi B, Liang F, et al. Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery? World J Surg Oncol. 2008 Nov 12;6:123.Texto completo  Resumen

76. Venkat R, Edil BH, Schulick RD, et al. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg. 2012 Jun;255(6):1048-59. Resumen

77. van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362:129-137.Texto completo  Resumen

78. Andriulli A, Festa V, Botteri E, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012 May;19(5):1644-62. Resumen

79. Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010 Apr 20;7(4):e1000267.Texto completo  Resumen

80. Morganti AG, Massaccesi M, La Torre G, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 2010 Jan;17(1):194-205. Resumen

81. Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC Trial. J Clin Oncol. 2020 Jun 1;38(16):1763-73. Resumen

82. Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(23):2082-8.Texto completo  Resumen

83. Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis. Eur J Surg Oncol. 2018 Oct;44(10):1619-23. Resumen

84. ClinicalTrials.gov. Neoadjuvant modified FOLFIRINOX and stereotactic body radiation therapy in borderline resectable pancreatic adenocarcinoma. ClinicalTrials.gov Identifier: NCT03099265. Jul 2021 [internet publication].Texto completo

85. ClinicalTrials.gov. Neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer. ClinicalTrials.gov Identifier: NCT02717091. Sep 2020 [internet publication].Texto completo

86. Conroy T, Castan F, Lopez A, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: A randomized clinical trial. JAMA Oncol. 2022 Sep 1:e223829. Resumen

87. Neoptolemos JP, Palmer D, Ghaneh P, et al. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 2016;34 (Suppl 15):LBA4006.Texto completo

88. Stocken DD, Büchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005 Apr 25;92(8):1372-81.Texto completo  Resumen

89. Butturini G, Stocken DD, Wente MN, et al; Pancreatic Cancer Meta-Analysis Group. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008 Jan;143(1):75-83.Texto completo  Resumen

90. Picozzi VJ, Pisters PW, Vickers SM, et al. Strength of the evidence: adjuvant therapy for resected pancreatic cancer. J Gastrointest Surg. 2008 Apr;12(4):657-61. Resumen

91. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008 Mar 5;299(9):1019-26.Texto completo  Resumen

92. Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011 May;18(5):1319-26.Texto completo  Resumen

93. Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014 Feb 20;32(6):504-12.Texto completo  Resumen

94. van Roessel S, van Veldhuisen E, Klompmaker S, et al. Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment. JAMA Oncol. 2020 Nov 1;6(11):1733-40.Texto completo  Resumen

95. Gurusamy KS, Kumar S, Davidson BR, et al. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev. 2014 Feb 27;(2):CD010244.Texto completo  Resumen

96. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703.Texto completo  Resumen

97. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25.Texto completo  Resumen

98. Kunzmann V, Siveke JT, Algül H, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-38.Texto completo  Resumen

99. Sultana A, Tudur Smith C, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer. 2008 Jul 8;99(1):6-13.Texto completo  Resumen

100. Sultana A, Smith CT, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007 Jun 20;25(18):2607-15.Texto completo  Resumen

101. Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008 Mar 28;8:82.Texto completo  Resumen

102. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960-6.Texto completo  Resumen

103. Heinemann V, Vehling-Kaiser U, Waldschmidt D, et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut. 2013 May;62(5):751-9. Resumen

104. Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016 May 3;315(17):1844-53. Resumen

105. Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016 Aug 1;34(22):2654-68.Texto completo  Resumen

106. Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014 Aug 10;32(23):2423-9.Texto completo  Resumen

107. Vickers MM, Powell ED, Asmis TR, et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer. 2012 Jul;48(10):1434-42. Resumen

108. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403-13. Resumen

109. Sultana A, Ghaneh P, Cunningham D, et al. Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer. 2008 Jul 8;8:192.Texto completo  Resumen

110. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Aug 10;27(23):3778-85.Texto completo  Resumen

111. Heinemann V, Labianca R, Hinke A, et al. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol. 2007 Oct;18(10):1652-9.Texto completo  Resumen

112. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 Nov 20;27(33):5513-8.Texto completo  Resumen

113. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010 Apr 1;28(10):1645-51.Texto completo  Resumen

114. Dahan L, Bonnetain F, Ychou M, et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut. 2010 Nov;59(11):1527-34.Texto completo  Resumen

115. Kulke MH, Tempero MA, Niedzwiecki D, et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20;27(33):5506-12.Texto completo  Resumen

116. Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545-57. Resumen

117. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731-9.Texto completo  Resumen

118. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-82.Texto completo  Resumen

119. US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. May 2017 [internet publication].Texto completo

120. ClinicalTrials.gov. A phase IIb pilot study to assess the efficacy, safety and pharmacodynamic effects of pembrolizumab and BL-8040 in patients with metastatic pancreatic cancer.ClinicalTrials.gov Identifier: NCT02907099. Apr 2018 [internet publication].Texto completo

121. ClinicalTrials.gov. Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies. ClinicalTrials.gov Identifier:NCT03095781. Apr 2018 [internet publication].Texto completo

122. ClinicalTrials.gov. A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (MK-3475) compared to CRT alone in patients with resectable or borderline resectable pancreatic cancer.ClinicalTrials.gov Identifier: NCT02305186. Sep 2017 [internet publication].Texto completo

123. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019 Jul 25;381(4):317-27.Texto completo  Resumen

124. Puli SR, Reddy JB, Bechtold ML, et al. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review. Dig Dis Sci. 2009 Nov;54(11):2330-7. Resumen

125. Kaufman M, Singh G, Das S, et al. Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer. J Clin Gastroenterol. 2010 Feb;44(2):127-34. Resumen

126. Arcidiacono PG, Calori G, Carrara S, et al. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007519.Texto completo  Resumen

127. Amr YM, Makharita MY. Comparative study between 2 protocols for management of severe pain in patients with unresectable pancreatic cancer: one-year follow-up. Clin J Pain. 2013 Sep;29(9):807-13. Resumen

128. National Institute for Health and Care Excellence. Pancreatic cancer. Quality statement 4: pancreatic enzyme replacement therapy. Dec 2018 [internet publication].Texto completo

129. ClinicalTrials.gov. A study of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion. ClinicalTrials.gov Identifier: NCT02912949. Jan 2021 [internet publication].Texto completo

130. ClinicalTrials.gov. A randomized phase 2/3 multi-center study of SM-88 in patients with metastatic pancreatic cancer. ClinicalTrials.gov Identifier: NCT03512756. Jun 2021 [internet publication].Texto completo

131. ClinicalTrials.gov. A multi-center trial to evaluate multiple regimens in metastatic pancreatic cancer. ClinicalTrials.gov Identifier: NCT04229004. Feb 2022 [internet publication].Texto completo

132. Vandell AG, Eckard J, Hoffman S, et al. In vitro and in vivo anticancer effects of D/L-alpha-metyrosine (SM-88), a novel metabolism-based therapy - Tyme Technologies, Inc. Jun 2020 [internet publication].Texto completo

133. ClinicalTrials.gov. The ASCEND study: gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma (ASCEND). ClinicalTrials.gov Identifier: NCT05042128. Jan 2022 [internet publication].Texto completo

134. Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review. JAMA. 2021 Sep 7;326(9):851-62. Resumen

135. Huguet F, Girard N, Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009 May 1;27(13):2269-77.Texto completo  Resumen

136. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(5 suppl):v56-68.Texto completo  Resumen

137. Nakchbandi IA, Lohr JM. Coagulation, anticoagulation and pancreatic carcinoma. Nat Clin Pract Gastroenterol Hepatol. 2008 Aug;5(8):445-55. Resumen

138. Kocher HM, Alrawashdeh W. Pancreatic cancer. BMJ Clin Evid. 2010 May 19;2010.Texto completo  Resumen

139. Gurusamy KS, Koti R, Fusai G, et al. Somatostatin analogues for pancreatic surgery. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008370.Texto completo  Resumen

140. Figueras J, Sabater L, Planellas P, et al. Randomized clinical trial of pancreaticogastrostomy versus pancreaticojejunostomy on the rate and severity of pancreatic fistula after pancreaticoduodenectomy. Br J Surg. 2013 Nov;100(12):1597-605. Resumen

141. Topal B, Fieuws S, Aerts R, et al; Belgian Section of Hepatobiliary and Pancreatic Surgery. Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial. Lancet Oncol. 2013 Jun;14(7):655-62. Resumen

142. Wente MN, Shrikhande SV, Muller MW, et al. Pancreaticojejunostomy versus pancreaticogastrostomy: systematic review and meta-analysis. Am J Surg. 2007 Feb;193(2):171-83. Resumen

143. Klaiber U, Probst P, Knebel P, et al. Meta-analysis of complication rates for single-loop versus dual-loop (Roux-en-Y) with isolated pancreaticojejunostomy reconstruction after pancreaticoduodenectomy. Br J Surg. 2015 Mar;102(4):331-40. Resumen

144. Deng Y, He S, Cheng Y, et al. Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery. Cochrane Database Syst Rev. 2020 Mar 11;3:CD009621.Texto completo  Resumen

145. Tamandl D, Sahora K, Prucker J, et al. Impact of the reconstruction method on delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy: a prospective randomized study. World J Surg. 2014 Feb;38(2):465-75. Resumen

146. Shimoda M, Kubota K, Katoh M, et al. Effect of Billroth II or Roux-en-Y reconstruction for the gastrojejunostomy on delayed gastric emptying after pancreaticoduodenectomy: a randomized controlled study. Ann Surg. 2013 May;257(5):938-42. Resumen

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad